发明名称 Glycine transporter-1 inhibitors, methods of making them, and uses thereof
摘要 The compounds of the present invention are represented by the following formula (I):; wherein the substituents R1, R2, R3, R4, (R5)m, R6, A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which is created by or is dependent upon inhibiting GlyT-1.
申请公布号 US9045445(B2) 申请公布日期 2015.06.02
申请号 US201113151992 申请日期 2011.06.02
申请人 Albany Molecular Research, Inc. 发明人 Cioffi Christopher L.;Wolf Mark A.;Guzzo Peter R.;Liu Shuang;Sadalapure Kashinath
分类号 A61K31/496;C07D403/12;C07D295/26;C07D205/04;C07D207/48;C07D211/58;C07D213/71;C07D233/84;C07D241/04;C07D249/04;C07D309/14;C07D313/04;C07D405/12;C07D487/08 主分类号 A61K31/496
代理机构 LeClairRyan, a Professional Corporation 代理人 LeClairRyan, a Professional Corporation
主权项 1. A compound of the formula (I): wherein: R1 is phenyl independently substituted from 1 to 5 times with halogen, C1-C3 alkyl, C3-C6 cycloalkyl, OR9, or SR10, wherein C1-C3 alkyl and C3-C6 cycloalkyl are optionally substituted with 1 to 10 times with R7; R2 is H; R3 and R4 are each individually H or CH3; R5 is selected from the group consisting of: (1) hydrogen,(2) C1-C6 alkyl which is optionally substituted from 1 to 11 times with R7,(3) gem-dialkyl, and(4) gem-dihalo; or two R5 substituents on the same carbon, together with the carbon atom to which they are attached, may form a 3-, 4-, or 5-membered cycloalkyl optionally substituted from 1 to 10 times with R7; or two R5 substituents on adjacent carbons of the ring to which they are attached, together may form a 3-, 4-, 5- or 6-membered cycloalkyl optionally substituted from 1 to 10 times with R7; R6 is wherein E, F, and G are each independently nitrogen or carbon and R6a is C1-C2 alkyl, which is optionally substituted 1 to 5 times with halogen or deuterium; R7 is selected from the group consisting of: (1) hydrogen,(2) halogen,(3) deuterium,(4) gem-dialkyl,(5) gem-dihalo,(6) —OR9, —NR11R12, —NR11C(O)pR10, —S(O)pR10, —CN, —NO2, —C(O)pR10, — C(O)NR11R12, or —NR11C(S)R10, and(7) oxo or thio; R8 is selected from the group consisting of: (1) hydrogen,(2) halogen,(3) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C4-C7 cycloalkylalkyl, wherein each of the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, and C4-C7 cycloalkylalkyl is independently and optionally substituted from 1 to 11 times with R7, or(4) —OR9, —NR11R12, —NR11C(O)pR10, —S(O)pR10, —CN, —NO2, —C(O)pR10, —C(O)NR11R12, or —NR11C(S)R10; R9 is selected from the group consisting of hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl, C4-C7 cycloalkylalkyl, —C(O)NR11R12, and —C(O)pR10, wherein each of C1-C4 alkyl, C3-C7 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 11 times with R7; R10 is selected from the group consisting of hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl C4-C7 cycloalkylalkyl, aryl, and heteroaryl, wherein each of C1-C4 alkyl, C3-C7 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 11 times with substituents as defined in R7 and aryl or heteroaryl is optionally substituted from 1 to 10 times with R8; R11 and R12 are each independently selected from the group consisting hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl, C4-C7 cycloalkylalkyl, aryl, and heteroaryl, wherein each of C1-C4 alkyl, C3-C7 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 11 times with substituents as defined in R7 and aryl or heteroaryl is optionally substituted from 1 to 10 times with R8, or R11 and R12 are taken together with the nitrogen to which they are attached to form a saturated or partially saturated monocyclic or fused bicyclic heterocycle optionally substituted from 1 to 11 times with R7; A is X is N; Y is N; p is 1, or 2; and m is 0; with the following provisos that: R6 cannot be (a) 1H-1,2,3-triazol-4-yl, or (b) 5-methylisoxazol-4-yl; or an oxide thereof, a pharmaceutically acceptable salt thereof, or an individual enantiomer or diastereomer thereof.
地址 Albany NY US